JP2010532657A - クレブシエラ属の抗原 - Google Patents

クレブシエラ属の抗原 Download PDF

Info

Publication number
JP2010532657A
JP2010532657A JP2010504730A JP2010504730A JP2010532657A JP 2010532657 A JP2010532657 A JP 2010532657A JP 2010504730 A JP2010504730 A JP 2010504730A JP 2010504730 A JP2010504730 A JP 2010504730A JP 2010532657 A JP2010532657 A JP 2010532657A
Authority
JP
Japan
Prior art keywords
seq
amino acids
antigen
nucleic acid
klebsiella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010504730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532657A5 (https=
Inventor
シャーミラ バクシ
トマス シップス
マルクス ハナー
ジュッタ ピカロ
クリスティーナ サッケ
エスター ナージ
アーバン ランドバーグ
ダグマー ツィーレル
アンドリアス メインケ
ビルギット ノイジス
ウルリケ シュティーアシュナイダー
ガバイン アレクサンダー ボン
Original Assignee
インターセル アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターセル アーゲー filed Critical インターセル アーゲー
Publication of JP2010532657A publication Critical patent/JP2010532657A/ja
Publication of JP2010532657A5 publication Critical patent/JP2010532657A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2010504730A 2007-05-02 2008-04-29 クレブシエラ属の抗原 Pending JP2010532657A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07107344 2007-05-02
PCT/EP2008/055214 WO2008135446A2 (en) 2007-05-02 2008-04-29 Klebsiella antigens

Publications (2)

Publication Number Publication Date
JP2010532657A true JP2010532657A (ja) 2010-10-14
JP2010532657A5 JP2010532657A5 (https=) 2011-07-14

Family

ID=39708006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504730A Pending JP2010532657A (ja) 2007-05-02 2008-04-29 クレブシエラ属の抗原

Country Status (7)

Country Link
US (3) US8236326B2 (https=)
EP (5) EP2489673A3 (https=)
JP (1) JP2010532657A (https=)
CN (1) CN102015754A (https=)
AU (1) AU2008248755A1 (https=)
CA (1) CA2685805A1 (https=)
WO (1) WO2008135446A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2489673A3 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
EP2326662B1 (en) * 2008-08-28 2016-11-23 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
US9169477B2 (en) 2012-01-27 2015-10-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for immunization against bacteria expressing a carbapenemase
KR101605846B1 (ko) * 2013-11-20 2016-03-23 한국과학기술연구원 클렙시엘라 뉴모니아에 특이적으로 결합하는 단일가닥 핵산 앱타머 및 이를 이용한 클렙시엘라 뉴모니아 검출 방법
WO2016113252A2 (en) * 2015-01-12 2016-07-21 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting klebsiella pneumoniae
EP3319628A2 (en) 2015-07-10 2018-05-16 Epitopix, LLC Proteins and immunizing compositions containingklebsiella
HK1252350A1 (zh) * 2015-08-24 2019-05-24 Medimmune, Llc Mrka多肽、抗体及其用途
KR20180083869A (ko) * 2015-10-28 2018-07-23 알사니스 바이오사이언시스 게엠베하 케이. 뉴모니애 (K. pneumoniae)의 만난-기반 O-항원을 표적화 하는 항체
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
EP3497124A1 (en) 2016-08-12 2019-06-19 ARSANIS Biosciences GmbH Klebsiella pneumoniae o3 specific antibodies
US11117956B2 (en) 2016-10-19 2021-09-14 Medimmune, Llc Anti-O1 antibodies and uses thereof
CN110540595B (zh) * 2018-12-20 2021-04-06 湖北工业大学 一种肺炎克雷伯菌抗体乳胶微球免疫层析检测试纸的制备方法
CN110540599B (zh) * 2018-12-20 2021-04-06 湖北工业大学 基于肺炎克雷伯菌表面蛋白抗体的肺炎克雷伯菌Elisa检测试剂盒及制备方法
CN110540600B (zh) * 2018-12-20 2021-01-29 湖北工业大学 基于肺炎克雷伯菌表面蛋白的乳胶微球免疫层析试纸的制备方法
CN111150839A (zh) * 2019-12-17 2020-05-15 中国科学院深圳先进技术研究院 一种用于免疫接种的组合物及其制备方法
CN112505324A (zh) * 2020-11-06 2021-03-16 杭州迅耀生物科技有限公司 一种新型冠状病毒检测方法
CN120775040A (zh) * 2021-08-25 2025-10-14 北京三诺佳邑生物技术有限责任公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
CN115838431A (zh) * 2022-07-08 2023-03-24 中国人民解放军陆军军医大学 一种用作肺炎克雷伯菌疫苗抗原的融合蛋白KP-Ag2及其应用
WO2025177313A1 (en) * 2024-02-23 2025-08-28 Bharat Serums And Vaccines Limited Antibodies against klebsiella pneumoniae and implementations thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
ES2120949T4 (es) 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
JP2001504448A (ja) 1996-08-30 2001-04-03 フュルステ，イェンス，ペーター 核酸の鏡面対称選択および進化
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1272215B1 (en) 2000-04-14 2007-10-10 Intercell AG Pharmaceutical preparations comprising modified peptides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2001281812B2 (en) 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
US20040170642A1 (en) 2000-08-17 2004-09-02 Jorg Fritiz Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP4188092B2 (ja) 2001-05-21 2008-11-26 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシ核酸分子
JP2005519035A (ja) 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
EP1740604A2 (en) * 2004-04-27 2007-01-10 Intercell AG Td antigens
EP2489673A3 (en) * 2007-05-02 2012-09-12 Intercell AG Klebsiella antigens
DE102012005675A1 (de) 2012-03-21 2013-09-26 Daimler Ag Kraftfahrzeugantriebsstrangvorrichtung mit einem Mehrgruppengetriebe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics

Also Published As

Publication number Publication date
EP2152731A2 (en) 2010-02-17
US8236326B2 (en) 2012-08-07
EP2489673A2 (en) 2012-08-22
EP2360177A1 (en) 2011-08-24
AU2008248755A1 (en) 2008-11-13
WO2008135446A3 (en) 2009-03-12
US20130230526A9 (en) 2013-09-05
EP2489673A3 (en) 2012-09-12
EP2338902A1 (en) 2011-06-29
CA2685805A1 (en) 2008-11-13
US20110236410A1 (en) 2011-09-29
US20140212448A1 (en) 2014-07-31
WO2008135446A2 (en) 2008-11-13
EP2497779A1 (en) 2012-09-12
EP2338902A8 (en) 2011-08-03
US8637052B2 (en) 2014-01-28
CN102015754A (zh) 2011-04-13
US20130011403A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US8236326B2 (en) Klebsiella antigens
US8349336B2 (en) Streptococcus pyogenes antigens
CA2818827C (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
CA2218601A1 (en) Treatment for verotoxin-producing escherichia coli
CZ125097A3 (cs) Vakcina a antitoxin pro léčbu a prevenci onemocnění C. difficile
KR20090019007A (ko) 스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
CN106103469B (zh) 突变型葡萄球菌抗原
EP2661500A2 (en) Clostridium difficile antigens
CN115038461A (zh) FimH突变体、其组合物及其用途
US6942861B2 (en) Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
Malekshahi et al. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin
AU2014253685A1 (en) Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
Zhang et al. Potential therapeutic effects of egg yolk antibody (Igy) in helicobacter pylori infections─ A review
TWI745323B (zh) 脂化之肺炎鏈球菌抗原組合物、製備方法及用途
Parma et al. Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy
JP2001503606A (ja) Ｈｅｌｉｃｏｂａｃｔｅｒ ｐｙｌｏｒｉアドヘシン結合型抗原
JP2007524366A (ja) ピロリ菌抗原
US9802988B2 (en) Engineered type IV pilin of Clostridium difficile
McNeilly et al. IgA and IgG antibody responses following systemic immunization of cattle with native H7 flagellin differ in epitope recognition and capacity to neutralise TLR5 signalling
WO2022207657A1 (en) Immunogenic fusion protein
Chitra Egg yolk antibodies (IgY) and its therapeutic uses for human and animal health-A review
WO2022125928A1 (en) Methods and compositions for improved production of an antigen for use in an s. aureus vaccine
EA050404B1 (ru) Мутанты fimh, композиции с ними и их применение
Fegan et al. Rational selection of TbpB variants yields a bivalent vaccine with broad coverage

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130708